AIHELP Committee markup of eight bipartisan health bills amid amendment dispute

Health Care Costs and Drug PricingSenate Health, Education, Labor, and Pensions · 2026-06-17 · 119th Congress
The Senate Health, Education, Labor, and Pensions Committee held an open business meeting to mark up eight bipartisan bills covering organ transplant discrimination, community health centers, stem cell therapy, breast health education, ALS therapies, and pharmaceutical patent and citizen-petition reforms. Begins at 0:18:37
Transcript
Highlights

Title

HELP Committee markup of eight bipartisan health bills amid amendment dispute

Purpose

The Senate Health, Education, Labor, and Pensions Committee held an open business meeting to mark up eight bipartisan bills covering organ transplant discrimination, community health centers, stem cell therapy, breast health education, ALS therapies, and pharmaceutical patent and citizen-petition reforms. Chair Cassidy opened by objecting to a slate of Democratic amendments he called non-germane "poison pills" that could derail the underlying bipartisan bills, while Ranking Member Sanders defended the amendments as addressing a healthcare and primary-care workforce crisis. Most Sanders amendments were tabled along party lines, and the committee ultimately reported six bills favorably, with S.3014 held pending further work on an added insulin provision. Begins at0:18:37

Who spoke

Chair Bill Cassidy (R-LA)0:18:37: Opened by criticizing Ranking Member Sanders' non-germane "poison pill" amendments as threatening to derail eight bipartisan bills0:19:20, repeatedly moved to table Sanders' amendments citing lack of CBO scoring and technical assistance0:43:47, and guided the markup through final passage of six bills2:01:41.

Sen. Bernie Sanders (I-VT), Ranking Member0:24:21: Argued the U.S. spends twice as much per capita on health care as other nations while 85 million are un/underinsured and ~60,000-65,000 die yearly from lack of care access0:25:51; offered nine amendments on community health centers, teaching health centers, National Health Service Corps funding, nurse faculty funding, drug ad bans, most-favored-nation drug pricing, and student loan provisions0:29:111:19:291:24:201:32:46, nearly all of which were tabled.

Sen. Ashley Moody (R-FL)0:32:47: Championed S.1782 (Charlotte Woodward Act), citing constituent Charlotte Woodward's presence and the story of "Baby Zion," who died in 2021 after being denied a heart transplant due to Down syndrome0:33:170:33:44.

Sen. Maggie Hassan (D-NH)0:34:28: Voiced support for S.1782 on behalf of people with disabilities0:34:28; later championed S.2658's patent-integrity provisions targeting big pharma's inconsistent FDA/PTO filings1:46:58 and opposed amendments she said would gut the bill's enforcement mechanism1:55:03.

Sen. Tim Kaine (D-VA)0:35:02: Offered an amendment to S.1782 blocking the shift of special education/rehabilitation services to HHS, citing the administration's move to reassign Department of Education functions0:35:58; withdrew it after Cassidy committed to a vote at the July markup0:39:20.

Sen. Susan Collins (R-ME)0:44:10: Explained S.3014 (Ensuring Timely Access to Generics Act), noting brand manufacturers filed ~86% of citizen petitions from 2016-2019, over 90% of which the FDA rejected, and citing a CBO estimate of $49 million in taxpayer savings0:45:050:45:48; defended the Special Diabetes Program funding she secured as Appropriations chair0:59:06.

Sen. Roger Marshall (R-KS)0:57:25: Said community health centers need better outcome measurement rather than more funding without accountability0:57:55; later explained his managers amendment to S.3799 aligning Healthy Start funding with FY2026 appropriations1:37:47.

Sen. Lisa Murkowski (R-AK)1:15:25: Objected to a Sanders nursing faculty amendment being sprung on her and Sen. Durbin's ongoing bipartisan negotiation1:15:56; later spoke on S.4472 (ALS Act), entering a statement from Sen. Coons and naming advocates Dan Tate, Brian Wallick, Jenny Dwyer, and Eric Dane1:43:31.

Sen. Rick Scott (R-FL)1:39:52: Praised the stem cell/bone marrow transplant bill (S.4109), citing 150,000 transplants performed and benefits for lymphoma, blood cancer, and sickle cell anemia patients1:39:52.

Sen. Josh Hawley (R-MO)1:47:57: Co-sponsored S.2658, accusing big pharma of telling the FDA and patent office different things to block generic competition1:48:11; opposed amendments he said would remove the bill's enforcement mechanism1:56:21.

Sen. Jim Banks (R-IN)1:49:15: Offered an amendment to S.2658 to protect trade secrets from Chinese Communist Party exploitation of patent disclosures1:49:15, which failed 8-131:53:36.

Sen. Jon Husted (R-OH)1:53:58: Offered two amendments to S.2658 - one requiring a "material effect" standard for FDA/PTO filing mismatches (failed 8-13)1:53:581:58:26, and one barring foreign-adversary-tied entities from using the bill's defense, adopted by voice vote1:59:132:01:12.

Key moments

Cassidy accused Sanders of filing non-germane, unpaid-for "poison pill" amendments two days before markup that risk sabotaging bipartisan bills0:19:500:30:11; Sanders countered that his amendments—on community health centers and workforce shortages—reflect widely supported priorities, not poison pills0:25:510:30:02.

Sanders' amendment to add insulin-pricing provisions (Sanders Amendment 6) passed 15-8 after a failed motion to table (8-15)0:50:52, with Cassidy noting Sanders never brought the Insulin Act to a vote when he chaired the committee in 20230:41:37.

Cassidy noted community health centers face a projected $42 billion revenue loss over five years (per George Washington University) and a possible one million more uninsured patients, per Sanders0:28:44; his subsequent amendment to raise CHC funding from $4.6B to $5.8B was tabled 12-111:03:25.

Sanders' amendment to ban pharmaceutical TV advertising cited HHS Secretary Kennedy's public support for such a ban and noted the U.S. and New Zealand are the only countries permitting such ads; Cassidy called it unconstitutional under First Amendment precedent and it was tabled 12-111:20:261:23:07.

Sanders' most-favored-nation drug pricing amendment (No. 8) claimed it would cut a Crohn's disease drug from $152,000 to $21,000 a year and a cancer drug from $210,000 to $88,0001:26:36; Collins objected to its use of "quality adjusted life years" metrics and the amendment failed to be tabled (11-11) but also failed adoption (11 ayes)1:27:401:32:40.

Kaine withdrew his S.1782 amendment on special education services after Cassidy publicly committed to a vote—either on a bipartisan fix or Kaine's standalone bill—at the July markup0:39:200:40:09.

Banks' amendment protecting trade secrets from Chinese exploitation of PTO disclosures failed 8-13, with Hawley arguing pharma companies keep shifting objections to delay the bill each time changes are made1:51:571:53:36.

Committee voted 22-0 to favorably report six bills as a block (S.1782, S.3799, S.4109, S.2339, S.4472, S.1954)2:04:19, then separately passed S.2658 as amended 16-62:05:36; Cassidy declined to bring S.3014 to final passage, citing continued work needed with Collins on the insulin provision2:01:41.

Marshall's Healthy Start amendment realigning funding to FY2026 appropriations levels was adopted by voice vote1:38:46.

Cassidy warned that if Democrats pursue partisan amendments, the bipartisan bills "will be denied the opportunity for future markups" in July0:23:15.

Metadata

Official titleBusiness meeting to consider S.1782, to prohibit discrimination on the basis of mental or physical disability in cases of organ transplants, S.3799, to amend the Public Health Service Act to reauthorize the Healthy Start Initiative, S.4109, to reauthorize the Stem Cell Therapeutic and Research Act of 2005, S.2339, to reauthorize the Young Women's Breast Health Education and Awareness Requires Learning Young Act of 2009, S.4472, to amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, S.2658, to require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office, S.3014, to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions, and S.1954, to improve the requirements for making a determination of interchangeability of a biological product and its reference product.
CommitteeSenate Health, Education, Labor, and Pensions
Chamber / CongressSenate · 119th Congress
Date2026-06-17
TypeOpen Business Meeting
Witnesses
(none listed in event metadata)
Videosenate-isvp
Transcript330 caption blocks · 13,617 words · 2:06:26 runtime
EventCongress.gov 338564